SG10201912366YA - Anti-cd3 antibody and molecules comprising the antibody - Google Patents

Anti-cd3 antibody and molecules comprising the antibody

Info

Publication number: SG10201912366YA
Authority: SG; Singapore
Prior art keywords: antibody; molecules
Prior art date: 2016-12-22

Application number

SG10201912366YA

Other languages

English (en)

Inventor

Tohru Takahashi

Chigusa Yoshimura

Shiho Kozuma

Kensuke Nakamura

Chikako Suzuki

Junya Ichikawa

Original Assignee

Daiichi Sankyo Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-22

Filing date

2017-12-21

Publication date

2020-02-27

2017-12-21 Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd

2020-02-27 Publication of SG10201912366YA publication Critical patent/SG10201912366YA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

SG10201912366YA 2016-12-22 2017-12-21 Anti-cd3 antibody and molecules comprising the antibody SG10201912366YA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2016249148		2016-12-22

Publications (1)

Publication Number	Publication Date
SG10201912366YA true SG10201912366YA (en)	2020-02-27

Family

ID=62627719

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201912366YA SG10201912366YA (en)	2016-12-22	2017-12-21	Anti-cd3 antibody and molecules comprising the antibody

Country Status (22)

Country	Link
US (2)	US11618785B2 (fr)
EP (2)	EP4606383A3 (fr)
JP (3)	JP7202185B2 (fr)
KR (1)	KR102682146B1 (fr)
CN (2)	CN110431231B (fr)
AU (2)	AU2017379382B9 (fr)
BR (1)	BR112019012901A2 (fr)
CA (1)	CA3048174A1 (fr)
CO (1)	CO2019007823A2 (fr)
DK (1)	DK3561057T3 (fr)
ES (1)	ES3039621T3 (fr)
FI (1)	FI3561057T3 (fr)
HR (1)	HRP20251051T1 (fr)
HU (1)	HUE073284T2 (fr)
IL (2)	IL311136A (fr)
LT (1)	LT3561057T (fr)
MX (1)	MX2019007347A (fr)
PH (1)	PH12019501387A1 (fr)
SG (1)	SG10201912366YA (fr)
SI (1)	SI3561057T1 (fr)
TW (2)	TWI854953B (fr)
WO (1)	WO2018117237A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7202185B2 (ja) *	2016-12-22	2023-01-11	第一三共株式会社	抗ｃｄ３抗体及び該抗体を含む分子
TW202016144A (zh) *	2018-06-21	2020-05-01	日商第一三共股份有限公司	包括cd3抗原結合片段之組成物及其用途
CN109776683B (zh) *	2019-03-19	2020-04-07	益科思特(北京)医药科技发展有限公司	一种双特异性抗体及其制备方法与应用
MX2021014973A (es) *	2019-06-07	2022-04-18	Adimab Llc	Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
WO2020261280A1 (fr) *	2019-06-25	2020-12-30	Ichilov Tech Ltd.	Anticorps anti-cd24 et utilisations de celui-ci
PH12022500012A1 (en) *	2020-03-30	2023-04-03	Daiichi Sankyo Co Ltd	Bispecific antibody
JP7789368B2 (ja) *	2020-05-29	2025-12-22	学校法人久留米大学	炎症性腸疾患に対する治療用抗体
WO2022046658A1 (fr) *	2020-08-24	2022-03-03	Janux Therapeutics, Inc.	Anticorps ciblant trop2 et cd3, et leurs utilisations
CN114656562B (zh) *	2020-12-23	2023-11-03	北京天广实生物技术股份有限公司	结合人和猴cd3的抗体及其应用
CA3214264A1 (fr)	2021-03-29	2022-10-06	Daiichi Sankyo Company, Limited	Molecule multispecifique stable et son utilisation
EP4416182A4 (fr) *	2021-10-12	2025-09-17	Lepu Biopharma Co Ltd	Anticorps anti-cd3 avec réactivité croisée vis-à-vis des protéines humaines et de cynomolgus
US20250223358A1 (en) *	2022-03-09	2025-07-10	Antengene Biologics Limited	Novel anti-cd3 antibodies and uses thereof
US20230295310A1 (en) *	2022-03-20	2023-09-21	Abcellera Biologics Inc.	CD3 T-Cell Engagers and Methods of Use
JP2025510266A (ja) *	2022-03-25	2025-04-14	嘉和生物▲薬▼▲業▼有限公司	Ｃｄ３を標的とする抗体及びその使用
AU2023312397A1 (en)	2022-07-29	2025-03-13	Zymeworks Bc Inc.	Multivalent and bispecific antibody constructs and methods of use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DK0585287T3 (da)	1990-07-10	2000-04-17	Cambridge Antibody Tech	Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
EP0605522B1 (fr)	1991-09-23	1999-06-23	Medical Research Council	Méthodes de production d'anticorps humanisés
PT1024191E (pt)	1991-12-02	2008-12-22	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2131151A1 (fr)	1992-03-24	1994-09-30	Kevin S. Johnson	Methodes de production d'elements formant des paires specifiques de liaison
GB9313509D0 (en)	1993-06-30	1993-08-11	Medical Res Council	Chemisynthetic libraries
WO1995015388A1 (fr)	1993-12-03	1995-06-08	Medical Research Council	Proteines et peptides de liaison recombines
US6214388B1 (en)	1994-11-09	2001-04-10	The Regents Of The University Of California	Immunoliposomes that optimize internalization into target cells
US6972323B1 (en)	1997-04-01	2005-12-06	Sankyo Company, Limited	Anti-Fas antibodies
DK1071700T3 (da)	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
DE19819846B4 (de)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalente Antikörper-Konstrukte
CA2704600C (fr)	1999-04-09	2016-10-25	Kyowa Kirin Co., Ltd.	Methode de production d'anticorps avec activite adcc accrue
JP3871503B2 (ja)	1999-08-30	2007-01-24	日本たばこ産業株式会社	免疫性疾患治療剤
JP2003531588A (ja)	2000-04-11	2003-10-28	ジェネンテック・インコーポレーテッド	多価抗体とその用途
CA2953239A1 (fr)	2000-10-06	2002-04-18	Kyowa Hakko Kirin Co., Ltd.	Cellules produisant des compositions d'anticorps
SI1583830T1 (sl)	2003-01-07	2006-12-31	Symphogen As	Postopek za pripravo rekombinantnih poliklonskih proteinov
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
EP1940881B1 (fr)	2005-10-11	2016-11-30	Amgen Research (Munich) GmbH	Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
EP2006379B1 (fr)	2006-03-23	2016-08-31	Tohoku University	Anticorps bispecifique hautement fonctionnel
RS53008B2 (sr)	2007-04-03	2022-12-30	Amgen Res Munich Gmbh	Interspecijski specifičan cd3-epsilon vezujući domen
RU2769948C2 (ru)	2007-04-03	2022-04-11	Эмджен Рисерч (Мьюник) Гмбх	CD3-Эпсилон-связывающий домен с межвидовой специфичностью
EP2352765B1 (fr) *	2008-10-01	2018-01-03	Amgen Research (Munich) GmbH	Anticorps monocaténaire bispécifique à domaine unique, spécifique d'espèces croisées
EP2270053A1 (fr)	2009-05-11	2011-01-05	U3 Pharma GmbH	Anticorps AXL humanisés
AU2012245116A1 (en)	2011-04-20	2013-11-07	Genmab A/S	Bispecific antibodies against HER2 and CD3
KR102060389B1 (ko) *	2011-05-21	2019-12-31	마크로제닉스, 인크.	사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
EP2832856A4 (fr)	2012-03-29	2016-01-27	Chugai Pharmaceutical Co Ltd	Anticorps anti-lamp5 et son utilisation
WO2014122143A1 (fr)	2013-02-05	2014-08-14	Engmab Ag	Procédé de sélection d'anticorps anti-bcma
EP2839842A1 (fr)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
KR102813659B1 (ko)	2013-11-11	2025-05-28	추가이 세이야쿠 가부시키가이샤	개변된 항체 가변영역을 포함하는 항원 결합 분자
CN106459201A (zh) *	2014-05-28	2017-02-22	豪夫迈·罗氏有限公司	结合人和食蟹猴CD3ε的抗体
TWI831044B (zh) *	2014-11-11	2024-02-01	日商中外製藥股份有限公司	抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法
CN120988137A (zh) *	2015-01-23	2025-11-21	赛诺菲	抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
JP7202185B2 (ja) *	2016-12-22	2023-01-11	第一三共株式会社	抗ｃｄ３抗体及び該抗体を含む分子

2017
- 2017-12-21 JP JP2018558078A patent/JP7202185B2/ja active Active
- 2017-12-21 CN CN201780079717.1A patent/CN110431231B/zh active Active
- 2017-12-21 AU AU2017379382A patent/AU2017379382B9/en active Active
- 2017-12-21 MX MX2019007347A patent/MX2019007347A/es unknown
- 2017-12-21 CA CA3048174A patent/CA3048174A1/fr active Pending
- 2017-12-21 IL IL311136A patent/IL311136A/en unknown
- 2017-12-21 SG SG10201912366YA patent/SG10201912366YA/en unknown
- 2017-12-21 ES ES17884717T patent/ES3039621T3/es active Active
- 2017-12-21 DK DK17884717.4T patent/DK3561057T3/da active
- 2017-12-21 BR BR112019012901-4A patent/BR112019012901A2/pt unknown
- 2017-12-21 SI SI201731622T patent/SI3561057T1/sl unknown
- 2017-12-21 LT LTEPPCT/JP2017/046006T patent/LT3561057T/lt unknown
- 2017-12-21 HR HRP20251051TT patent/HRP20251051T1/hr unknown
- 2017-12-21 US US16/472,346 patent/US11618785B2/en active Active
- 2017-12-21 IL IL267567A patent/IL267567B2/en unknown
- 2017-12-21 FI FIEP17884717.4T patent/FI3561057T3/fi active
- 2017-12-21 WO PCT/JP2017/046006 patent/WO2018117237A1/fr not_active Ceased
- 2017-12-21 EP EP25183109.5A patent/EP4606383A3/fr active Pending
- 2017-12-21 EP EP17884717.4A patent/EP3561057B1/fr active Active
- 2017-12-21 CN CN202311689828.8A patent/CN118126180A/zh active Pending
- 2017-12-21 HU HUE17884717A patent/HUE073284T2/hu unknown
- 2017-12-21 KR KR1020197021178A patent/KR102682146B1/ko active Active
- 2017-12-22 TW TW106145218A patent/TWI854953B/zh active
- 2017-12-22 TW TW113129385A patent/TW202448957A/zh unknown
2019
- 2019-06-18 PH PH12019501387A patent/PH12019501387A1/en unknown
- 2019-07-19 CO CONC2019/0007823A patent/CO2019007823A2/es unknown
2022
- 2022-12-23 JP JP2022206884A patent/JP7478222B2/ja active Active
2023
- 2023-04-03 US US18/194,987 patent/US20230287119A1/en active Pending
2024
- 2024-04-19 JP JP2024068544A patent/JP2024091842A/ja active Pending
2025
- 2025-01-17 AU AU2025200368A patent/AU2025200368A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2023027374A (ja)	2023-03-01
RU2019122411A (ru)	2021-01-25
MX2019007347A (es)	2019-12-05
CN118126180A (zh)	2024-06-04
AU2017379382B9 (en)	2025-02-27
JPWO2018117237A1 (ja)	2019-10-31
EP3561057B1 (fr)	2025-07-23
EP3561057A4 (fr)	2020-09-16
US20230287119A1 (en)	2023-09-14
KR20190121294A (ko)	2019-10-25
CN110431231B (zh)	2024-01-02
TW201829467A (zh)	2018-08-16
JP7202185B2 (ja)	2023-01-11
CO2019007823A2 (es)	2019-10-09
IL267567B2 (en)	2024-08-01
TWI854953B (zh)	2024-09-11
DK3561057T3 (da)	2025-10-27
RU2019122411A3 (fr)	2021-03-05
BR112019012901A2 (pt)	2020-01-07
US11618785B2 (en)	2023-04-04
US20190359712A1 (en)	2019-11-28
IL311136A (en)	2024-04-01
IL267567A (fr)	2024-04-01
SI3561057T1 (sl)	2026-01-30
EP4606383A2 (fr)	2025-08-27
JP7478222B2 (ja)	2024-05-02
FI3561057T3 (fi)	2025-10-07
IL267567B1 (en)	2024-04-01
PH12019501387A1 (en)	2020-02-10
CA3048174A1 (fr)	2018-06-28
HUE073284T2 (hu)	2026-01-28
EP4606383A3 (fr)	2025-12-17
CN110431231A (zh)	2019-11-08
ES3039621T3 (en)	2025-10-23
JP2024091842A (ja)	2024-07-05
LT3561057T (lt)	2025-09-25
AU2017379382A1 (en)	2019-07-11
TW202448957A (zh)	2024-12-16
EP3561057A1 (fr)	2019-10-30
AU2017379382B2 (en)	2025-01-30
KR102682146B1 (ko)	2024-07-04
WO2018117237A1 (fr)	2018-06-28
HRP20251051T1 (hr)	2025-11-07
AU2025200368A1 (en)	2025-02-20

Publication	Publication Date	Title
ZA201905905B (en)	2022-05-25	Anti-gprc5d antibody and molecule comprising the antibody
IL268206A (en)	2019-09-26	Antibodies directed against bcma and their use
IL264970A (en)	2019-04-30	Anti-tim-3 antibodies and their use
IL274152B (en)	2021-02-28	Anti-galectin-9 antibodies and their uses
SG10201912366YA (en)	2020-02-27	Anti-cd3 antibody and molecules comprising the antibody
IL271477A (en)	2020-01-30	Anti-cd166 antibodies and their uses
IL267942B (en)	2022-04-01	Anti-cd73 antibodies and uses thereof
IL268734A (en)	2019-10-31	Anti-LAG-3 antibodies and uses thereof
IL268700A (en)	2019-10-31	Anti-PHF-tau antibodies and uses thereof
IL262782B1 (en)	2023-04-01	Antibodies against tl1a and uses thereof
SG11201808632YA (en)	2018-10-30	Anti-pacap antibodies and uses thereof
SG10201911972QA (en)	2020-02-27	Antibodies against tim3 and uses thereof
ZA201901935B (en)	2020-11-25	Anti-il-33 antibodies and uses thereof
IL269134A (en)	2019-11-28	Antibodies against PAR2 and their use
IL273157A (en)	2020-04-30	Antibodies specific to AXL and their uses
IL272476A (en)	2020-03-31	Anti-Apelin antibodies and their uses
GB201503812D0 (en)	2015-04-22	Antibody molecules and uses thereof
IL263242A (en)	2018-12-31	Cytosol-penetrating antibody and use thereof
IL266082A (en)	2019-06-30	Anti-chikv antibodies and their use
IL266049A (en)	2019-06-30	Antibodies against o1 and their uses
ZA201807132B (en)	2021-05-26	Humanized anti-basigin antibodies and the use thereof
IL264417A (en)	2019-02-28	Anti-o2 antibodies and their uses
AU2017271189A1 (en)	2019-01-24	Cytosol-penetrating antibody and use thereof
SG11202003585VA (en)	2020-05-28	Anti-vista antibody and use thereof
GB201712032D0 (en)	2017-09-06	Antibodies and uses thereof